

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

- 2022 Fourth-Quarter reported sales decline of 4.4% to \$23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%*
 - 2022 Fourth-Quarter earnings per share (EPS) of \$1.33 decreasing 24.9% and adjusted EPS of \$2.35 increasing by 10.3%*
-
- 2022 Full-Year reported sales growth of 1.3% to \$94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*
 - 2022 Full-Year earnings per share (EPS) of \$6.73 decreasing 13.8% and adjusted EPS of \$10.15 increasing by 3.6%*
-
- Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of \$10.50, reflecting growth of 3.5%*

New Brunswick, N.J. (January 24, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”

OVERALL FINANCIAL RESULTS

	Q4		
(\$ in Millions, except EPS)	2022	2021	% Change
Reported Sales	\$23,706	\$24,804	(4.4)%
Net Earnings	\$3,520	\$4,736	(25.7)%
EPS (diluted)	\$1.33	\$1.77	(24.9)%

	Full Year		
	2022	2021	% Change
Reported Sales	\$94,943	\$93,775	1.3%
Net Earnings	\$17,941	\$20,878	(14.1)%
EPS (diluted)	\$6.73	\$7.81	(13.8)%